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Abstract
Background: Quercetin, the predominant flavonoid, has been reported to lower the risk of
several cancers. This flavonoid found in onion, grapes, green vegetables, etc. has been shown to
possess potent antiproliferative effects against various malignant cells. This study was designed to
investigate its effects on insulin-like growth factors (IGFs) and their binding protein-3 (IGFBP-3)
proteins secretion and also apoptosis induction in the human prostate cancer cell line, PC-3.
Methods: We evaluated the secretion of IGF-I, -II and IGFBP-3 in quercetin treated cells by
immunoradiometric (IRMA) method. Apoptosis was studied in quercetin treated cells by TUNEL
and DNA fragmentation. Protein expressions of Bcl-2, Bcl-xL, Bax and caspase-3 were studied by
western blot.
Results: At a dose of 100 µM concentration, we observed increased IGFBP-3 accumulation in PC-
3 cells conditioned medium with a dose dependent increase with 2 fold over a base line, and
significantly reduced the both IGF-I and IGF-II levels. Apoptosis induction was also confirmed by
TUNEL assay. Bcl-2 and Bcl-xL protein expressions were significantly decreased and Bax and
caspase-3 were increased.
Conclusion: These results suggest that the decreased level of IGFs could be due to the increased
levels of IGFBP-3, because of the high binding affinity towards IGFs, thereby decreasing the cell
proliferation. The increased level of IGFBP-3 was associated with increased pro-apoptotic proteins
and apoptosis in response to quercetin, suggesting it may be a p53-independent effector of
apoptosis in prostate cancer cells.
Background
Much attention has focused on the growth hormones
antagonists from the natural sources for the treatment of
prostate cancer are being developed to block the activity of
IGFs or to promote the activity of IGFBP-3; these agents
may offer additional ways of stimulating apoptosis in
malignant cancer cells. Quercetin, a flavonoid found in
onion, grapes, green vegetables, etc. has been shown to
possess potent antiproliferative effects against various
malignant cells [1-3]. Recent report indicated that querce-
Published: 06 April 2006
Journal of Carcinogenesis 2006, 5:10 doi:10.1186/1477-3163-5-10
Received: 27 December 2004
Accepted: 06 April 2006
This article is available from: http://www.carcinogenesis.com/content/5/1/10
© 2006 Vijayababu et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Carcinogenesis 2006, 5:10 http://www.carcinogenesis.com/content/5/1/10
Page 2 of 9
(page number not for citation purposes)
tin inhibited the proliferation of rat prostate cancer cells
by interacting with IGF-I signaling pathway [4]. IGFBP-3
is a member of a family of specific high affinity binding
proteins that modify the mitogenic actions of IGFs by reg-
ulating their access to the IGF-I receptor (IGFRI). There is
still some ambiguity in determining the role of IGFBP-3 in
regulating IGF actions, with studies showing both
enhancement and inhibition of IGFs mitogenic effects
[5,6]. However, IGFBP-3 has been shown to have IGFRI-
independent anti-proliferative and proapoptotic effects.
IGFBP-3 is expressed in many tissues including prostate
[7] and others have demonstrated its growth inhibitory
effects in human prostate cancer cells [8,9] as well as in
IGFRI-null fibroblasts [10]. More recently, it has been sug-
gested that the anti-proliferative effects of IGFBP-3 may be
mediated via an induction of apoptosis. Indirect evidence
has come from reports that an increase in IGFBP-3 expres-
sion is associated with the induction of apoptosis [11-15].
High levels of recombinant nonglycosylated IGFBP-3 can
induce apoptosis in MCF-7 breast carcinoma cells,
although under some conditions these levels of exoge-
nous IGFBP-3 may induce apoptosis indirectly by seques-
tering anti-apoptotic IGFs from the IGFRI [14]. However,
no induction of apoptosis was observed in Hs578T breast
carcinoma cells exposed to exogenous IGFBP-3 alone
[16], although in this study IGFBP-3 augmented the cellu-
lar response to apoptotic stimuli. Studies by Rajah et al
[12] in prostate carcinoma cells and IGFRI-negative
mouse fibroblasts showed an induction of apoptosis by
both exogenous and endogenous IGFBP-3 and provide
the strongest evidence of an IGFRI-independent pro-
apoptotic role for IGFBP-3 in cancer cell growth. IGFBP-3
production was induced by potent growth inhibitory and
pro-apoptotic agents including transforming growth fac-
tor β1 [TGF-β1; 14], retinoic acid [17], and tumor necrosis
factor-a [18] with evidence that these agents mediate their
cellular effects through IGFBP-3. Furthermore, IGFBP-3 is
an established target of the tumor suppressor p53 [19,20].
The Bcl-2 family has been identified as an important reg-
ulator of mammalian cell death with both anti-apoptotic
(e.g.  Bcl-2 and Bcl-xL) and pro-apoptotic (e.g.  Bax and
Bad) members [21]. Members of this family regulate sus-
ceptibility to apoptosis, whereby over expression of Bcl-2
or Bcl-xL in relation to Bax promotes survival, but over
expression of Bax accelerates cell death. Bax over expres-
sion in prostate cancer cells leads to induction of apopto-
sis [22]. These Bcl-2 related proteins play a role in the cell
Effect of quercetin on PC-3 cell proliferation Figure 1
Effect of quercetin on PC-3 cell proliferation. 3 × 103 cells were plated in 24-well plates. After reaching 70–80% confluence, in 
the presence of 5% FBS, cells were treated with vehicle or with various concentrations of quercetin (25, 50, 75, and 100 µM) 
for 24 h, 48 h and 72 h. Proliferation of cells was quantitated by [3H] thymidine incorporation. Values represents % of control. 
Experiments were performed in triplicate, and SD was less than 10%. denotes the statistical significance at P < 0.05 level 
between control and quercetin treated using Student's Newman Keuls (SNK).
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proliferation and apoptosis of prostate cancer [23], sug-
gesting changes in the ratio of Bcl-2-related proteins may
be an important determinant in the response of prostate
cancer cells to apoptotic stimuli. Our previous study
showed that quercetin reduce, IGF-I protein secretion in
conditioned media, while IGFBP-3 was induced in pros-
tate cancer cells [24]. In this study, the effect of quercetin
on the induction of apoptosis in human prostate cancer
cells, which is a p53 negative cell line, was examined.
As quercetin is more readily consumed worldwide, it is
worth investigating the effects of quercetin on prostate
cancer. While, IGFs are capable of enhancing, prolifera-
tion and inhibiting apoptosis in normal and malignant
prostate epithelial cells by autocrine/paracrine actions,
IGFBP-3 is found to be pro apoptotic. So the present study
was aimed to investigate the effect of quercetin on IGFs
and IGFBP-3 secretion in PC-3 cells.
Materials and methods
Minimum Essential Medium (MEM), Fetal Bovine Serum
(FBS), Trypan Blue and quercetin were purchased from
Sigma Chemical Co., USA. Thymidine [3H] was purchased
from BRIT, Mumbai. Other chemicals were obtained from
Sisco Research Laboratories (SRL), India. All the chemi-
cals used were extra pure and were of culture grade. The
androgen-independent prostatic carcinoma PC-3 cell line
was procured from National Center for Cell Science
(NCCS), Pune, India. Quercetin was dissolved in DMSO.
DMSO in culture media never exceeded 0.1% (v/v), the
concentration known not to affect the cell proliferation
and IGFBP-3 production. Cell viability was tested by
Trypan Blue exclusion method. PC-3 cells were plated at 1
× 105 cells per well in 12-well plates in MEM containing
5% FBS. The growth inhibitory effect of quercetin was
studied using Thymidine [3H] incorporation. For IGF-I, -
II and IGFBP-3 assays, 1 × 106 cells were treated with quer-
cetin (25, 50, 75 and 100 µM) in conditioned medium
containing 0.1% Bovine serum albumin for 24 h and 48
h. The doses were selected based on of our previous stud-
ies [24].
Cell proliferation
Cell proliferation was assessed by Thymidine incorpora-
tion method [25]. During the final 4th h of quercetin treat-
ment, 1 µCi/well [3H] thymidine-containing medium was
added and incubated. Monolayers were rinsed twice with
ice-cold saline and fixed with 1 ml/well ice-cold metha-
nol-acetic acid mixture at 4°C for a minimum of 2 h. Cells
were solubilized in 0.5 ml of SDS and 250 µl of each lysate
was mixed with the scintillation fluid, before counting.
Analysis of conditioned media for IGF-I, -II and IGFBP-3 
secretion
IGF-I, -II and IGFBP-3 secretion in conditioned media of
control and quercetin treated PC-3 cells were quantitated
by immunoradiometrically (IRMA). Cells were seeded at
1 × 106 cells in each petri dishes and treated with quercetin
for 24 h and 48 h. Conditioned media were collected 24
h and 48 h later and analyzed for IGF-I, -II and IGFBP-3.
The results were expressed as ng/ml.
Effects of quercetin on Bcl-2, Bcl-xL, Bax and caspase-3 proteins expression in prostate cancer cell line (PC-3) Figure 2
Effects of quercetin on Bcl-2, Bcl-xL, Bax and caspase-3 proteins expression in prostate cancer cell line (PC-3). PC-3 cells were 
treated with indicated concentrations of quercetin for 24 h. Cell lysates were analyzed by Western blotting. Blots were incu-
bated with anti-Bcl-2, anti- Bcl-xL, Bax, caspase-3 and anti-β actin antibodies.
Quercetin 
Treatment  
Control  25 µ µ µ µM 50  µ µ µ µM 75  µ µ µ µM 100  µ µ µ µM 
IGF-I 
(ng/ml)  24 h  17.44 ± 
3.14
15.76 ± 
1.63
11.86 ± 
2.73
* ND ND 
48 h  19.00 ± 
2.23
14.00 ± 
1.80
* ND ND ND 
IGF-II 
(ng/ml) 
24 h  51.20 ± 
4.20
48.87   ± 
3.90
42.00 ± 
3.68
*
36.24 ± 
2.89
*
32.12 ± 
2.94
*
48 h  65.00 ± 
5.56
59.85 ± 
4.23
51.27 ± 
4.57
*
42.21 ± 
4.18
*
36.00 ± 
3.37
*
IGFBP-3
(ng/ml) 
24 h  32.49 ± 
2.21
35.17 ± 
3.15
40.22 ± 
3.64
*
64.85 ± 
5.40
*
67.52 ± 
4.15
*
48 h  36.80 ± 
4.12
38.30 ± 
3.60
45.60 ± 
3.80
*
56.80 ± 
4.50
*
64.60 ± 
5.13
*
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Western blotting of Bcl-2, Bcl-xL, Bax and caspase-3
Cells were plated on 75 cm2 flasks at density of 2 × 106
cells per flask, allowed to attach overnight and then
exposed to quercetin for 24 h. Control cells were exposed
to DMSO for 24 h. After the cells were washed three times
with 33ice-cold PBS, then total proteins were extracted by
adding 200 µl of cold lysis buffer (50 mM Tris-HCl, pH
7.4; 1 mM sodium Fluoride (NaF); 150 mM NaCl; 1 mM
EDTA; 1 mM phenylmethylsulphonyl fluoride (PMSF)
and 10 mg/ml leupeptin) to the cell pellets. After 30 min
on ice the cell debris was pelleted by centrifugation at 10
000 × g for 30 min at 4°C. The proteins were quantified
by Lowry's method [26]. The samples (50µg of total pro-
tein) were mixed with 5X sample buffer, containing 0.3 M
Tris-HCl (pH 6.8), 25% 2-mercaptoethanol, 12% sodi-
umdodecyl sulphate (SDS), 25 mM EDTA, 20% glycerol,
and 0.1% bromophenol blue. The mixtures were boiled at
95°C for 5 min, and subjected to 10–15% SDS-PAGE
(polyacrylamide gel electrophoresis) at a constant current
of 20 mA. Following electrophoresis, proteins on the gel
were electro-transferred onto a PVDF membrane (Sigma,
U.S.A.) in transfer buffer composed of 25 mM Tris-HCl
(pH 8.9), 192 mM glycine and 20% methanol. The mem-
branes were blocked with 20 mM Tris-HCl (pH 7.4), 125
mM NaCl, 0.2% Tween 20, 3% bovine serum albumin
(BSA), and 0.1% sodium azide. The membranes were
then immunoblotted with mouse monoclonal anti-
human Bcl-2, Bcl-xL, Bax, caspase-3 and β-actin antibodies
(generous gift from Dr. Ion V. Deaciuc, University of Lou-
isville, Kentucky, USA). The membranes were washed and
were incubated with horseradish peroxidase-labelled anti-
mouse Rabbit IgG antibody at a dilution of 1:1000. The
bands were developed using ECL kit (Perkin Elmer, USA)
and density of the bands was detected with scanning den-
sitometry.
Flowcytometry analysis
Cells were plated at 1 × 106 cells in a 25 cm2 flasks for 24
h. Cells were then washed with fresh media and treated
with 50 and 100 µM concentration of quercetin. 24 h
post-treatment, cells were trypsinized, and aliquots of 1 ×
106 cells were suspended in 1 ml of fluorochrome solu-
tion (50 mg/ml propidium iodide, 1 mg/ml RNase A,
1.5% Triton X–100) for at least 1 h in the dark at 4°C. Cell
cycle analysis was performed using a Beckman Vantage
flow cytometer.
DNA fragmentation
After 24 h and 48 h of treatment, the DNA was extracted
from the cell lysate as follows. Both attached and floating
cells were collected, washed with PBS and centrifuged at
1500 × g for 5 min to collect the cell pellet, which was
resuspended in 0.5 ml of lysis buffer, transferred to a
microfuge tube and incubated for 1 h at 37°C. To this, 4
µl of proteinase K (1 mg/ml) was added and the tubes
were incubated at 50°C for 3 h. To each tube, 0.5 ml of
phenol-chloroform-isoamyl alcohol (25: 24: 1) was
added, mixed and centrifuged at 10,000 × g for 1 min to
separate the DNA containing upper aqueous phase. To the
resulting aqueous phase, 2 vol of ice-cold absolute etha-
nol and 1/10 vol of 3 M sodium acetate were added and
incubated for 30 min on ice to precipitate DNA. DNA was
pelleted by centrifuging at 10, 000 × g for 10 minutes at
4°C, the supernatant was aspirated and the pellet was
washed with 1 ml of 70% ethanol. Then the DNA was
quantified by UV-visible spectroscopy and electro-
phoresed in a 1.2% agarose gel containing ethidium bro-
mide.
TUNEL
DNA strand breaks in apoptotic cells were measured by
terminal deoxynucleotidyl transferase mediated bioti-
nylated UTP nick end-labeling (TUNEL) using an in situ
cell death detection kit from Roche Molecular Biochemi-
cals, Germany. Treated cells were harvested and fixed with
4% paraformaldehyde solution and incubated in a 0.1%
Triton permeabilization solution on ice according to the
Effects of quercetin on cell cycle distribution in PC-3 cells Figure 3
Effects of quercetin on cell cycle distribution in PC-3 cells. 
PC-3 cells were treated with quercetin at doses of 50 and 
100 µM for 24 h in a 25 cm2 flasks. After treatment 1 × 106 
cells were trypsinized and suspended in 1 ml of fluoro-
chrome solution (50 mg/ml propidium iodide, 1 mg/ml RNase 
A, 1.5% Triton X-100) for at least 1 h in the dark at 4°C. Cell 
cycle analysis was performed using a Beckman Vantage flow 
cytometer, and quantitation of cell cycle distribution was 
performed using Multicycle software (Phoenix Flow Systems, 
San Diego, CA). Significant decrease in the proportions of 
cells in G1-S and increase in G2-M-phase, were evident after 
exposure to quercetin for 24 h. A concomitant increase of 
cells in SubG1-phase was observed in quercetin treated cells, 
indicating induction of apoptosis. The experiments were 
repeated thrice, *-denotes the statistical significance at P < 
0.05 level between control and quercetin treatment groups 
using Student's Newman Keuls (SNK) test.
Bax 
Bcl-2 
Bcl-xL
β-Actin
Control     50µM   100µM 
Caspase-3Journal of Carcinogenesis 2006, 5:10 http://www.carcinogenesis.com/content/5/1/10
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manufacturer's instructions. Cells incubated with the
solution without the terminal transferase was used as a
negative control.
Statistical analysis
The data were analyzed using the SPSS 7.5 Windows Stu-
dents version software. For all the measurements, one-
way ANOVA followed by Student's Newman Keuls (SNK)
test was used to assess the statistical significance of differ-
ence between control and quercetin-treated. A statistically
significant difference was considered to be at P < 0.05.
Results
Cell proliferation
PC-3 cells showed a significant decrease in thymidine [3H]
uptake. Fig.1 shows the kinetics of proliferation upto 0 –
72 h quercetin treatments, during which the thymidine
uptake was decreased between 3- and 4- fold in quercetin
treated cells. Time response data demonstrate 50% growth
inhibition at 100 µM for 24 h.
IGF-I, -II and IGFBP-3 level
After treatment of quercetin, the secretions of IGF-I,-II and
IGFBP-3 levels were measured in conditioned media by
immunoradiometric method. The secretion of IGF-I was
significantly reduced in conditioned media of quercetin
treated PC-3 cells. The IGF-II level was also significantly
reduced in conditioned media of quercetin treated PC-3
cells. Interestingly, the secretion of IGFBP-3 by quercetin
treated PC-3 cells was significantly increased in quercetin
treated conditioned medium of both 24 h and 48 h
treated experiments (Table-1).
Protein expression of Bcl-2, Bcl-xL, Bax and caspase-3
To investigate a possible intracellular mechanism for the
observed increase in apoptosis, we examined the protein
expression of the apoptotic intermediates of the Bcl-2
family. Quercetin treated cells were analyzed for protein
expression of pro-apoptotic Bax and caspase-3, and anti-
apoptotic Bcl-2 and Bcl-xL proteins by Western blotting
with specific antibodies. Protein levels were quantitated
by densitometry and expressed as a percentage of the con-
trol. As shown in Fig. 2, a strong 21-kDa band represent-
ing Bax protein was seen in quercetin treated lysate,
compared with a control. We then examined the Bcl-2 and
Bcl-xL proteins expression in quercetin treated prostate
cancer cells, we observed significant decrease of Bcl-2 and
Bcl-xL proteins (Fig. 2). Western blot analysis was also per-
A photograph of an UV light-illuminated agarose gel containing total cellular DNA; lanes were loaded with DNA preparations  made from 24 h and 48 h quercetin treated PC-3 cells with different concentrations Figure 4
A photograph of an UV light-illuminated agarose gel containing total cellular DNA; lanes were loaded with DNA preparations 
made from 24 h and 48 h quercetin treated PC-3 cells with different concentrations.
  
Phase Control  50 µM 100 µM 
Sub G1  9.8+ 0.8*  11+ 0.82* 
G1-S 80.2+ 6.8  68.6+ 6.1*  64+ 6.2* 
G2-M 19.8+ 1.1  21.6+ 1.2  25+ 1.6* 
100µ µ µ µM  50µ µ µ µM  Control Journal of Carcinogenesis 2006, 5:10 http://www.carcinogenesis.com/content/5/1/10
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formed to analyse caspase-3 (active fragment). As shown
in figure 2, quercetin increased the levels of caspase-3,
suggesting the possible involvement of caspase-3 activa-
tion as one of the possible mechanism of apoptosis induc-
tion.
Apoptosis
To analyze the mechanism responsible for the growth
inhibition of PC-3 cells by quercetin, the effects of querce-
tin on programmed cell death was examined. A concomi-
tant increase of cells in Sub G1-phase was observed in
quercetin treated cells, indicating induction of apoptosis
(Fig. 3). The sub G1 phase showed significant increase in
the cell number in quercetin treated when compared with
control. Significant decrease in the proportions of cells in
G and S phases was evident with increase in G2 M phase.
DNA agarose electrophoresis for quercetin treated cells
showed quercetin treatment caused DNA fragmentation
in the PC-3 cells (Fig. 4). Quantitative apoptotic cell death
was performed to confirm the induction of apoptosis.
Quercetin-caused apoptotic death of PC-3 cells was ana-
lysed by TUNEL assay, which showed that 50 and 100 µM
treatment of quercetin for 24 h significantly (P < 0.05)
increased the percentage of apoptotic cells up to 10 fold
compared with that of control (Fig. 5).
Discussion
The insulin like growth factors (IGFs) plays an increas-
ingly recognized role in the autocrine/paracrine regula-
tion of cancer cells. There is now accumulating evidence
that IGFBP-3 has an important anti-proliferative and pro-
apoptotic role in the regulation of cancer cell growth [27].
However, although it has been described, as an effector of
anticancer cancer agents-induced apoptosis, moreover
there are no reports available in the role IGFBP-3 in quer-
cetin-induced apoptosisin prostate cancer cells. This study
Effect of quercetin on induction of apoptosis in PC-3 cells Figure 5
Effect of quercetin on induction of apoptosis in PC-3 cells. The percentage of apoptotic cells was determined and summarized. 
Generation of free 3'-OH DNA fragments was determined by TUNEL assay. Each value is mean ± SEM. Experiments were car-
ried out in triplicates. *-represents statistical significance between control Vs quercetin treatment groups at P < 0.05 level using 
Student Newman-Keuls (SNK) test.
24 h  48 h
  24h          48h 
A-Control      F-Control 
B-25µM    G-25µM   
C-50µM         H-50µM 
D-75µM         I-75µM
E-100µM       J-100µM 
M- DNA 100 bp marker 
A  B   C   D   E          F   G   H   I    J    MJournal of Carcinogenesis 2006, 5:10 http://www.carcinogenesis.com/content/5/1/10
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examined the effects of quercetin on the induction of
apoptosis and possible mediating role of IGFBP-3. The
increased endogenous production ofIGFBP-3 by querce-
tin was associated with the induction of apoptosis in this
human prostate cancer cell line. This induction was
observed under serum-free conditions, suggesting possi-
ble pro-apoptotic role of IGFBP-3 in this cells. There are
reports suggesting that IGFBP-3 as effector of apoptosis
inducer in PC-3 cells [7,8,12]. This effect was observed in
cells not expressing functional p53 protein, so it was inde-
pendent of p53. This supports the work by Rajah et al. [13]
who demonstrated the proapoptotic function of IGFBP-3
in p53 negative prostate carcinoma cells (PC-3) as well as
IGFRI deficient mouse fibroblasts.
The induction of apoptosis by quercetin was associated
with changes in both pro-apoptotic and anti-apoptotic
members of the Bcl-2 family as well as caspase-3. The ratio
of pro-apoptotic Bax protein to anti-apoptotic proteins,
Bcl-2 and Bcl-xL is a crucial determinant of both cellular
susceptibility to apoptosis [21]. Normal prostate epithe-
lium expresses both Bax and Bcl-2 [22,23], the levels of
which may be regulated by androgen and estrogen and
other factors. IGFBP-3 expression might be one of the
modulator of the ratio of apoptotic proteins by up-regu-
lating the pro-apoptotic protein, Bax and down-regulating
Bcl-2 and Bcl-xL proteins in quercetin treated PC-3 cells.
There is evidence that anti-apoptotic signaling through
the IGFRI is associated with changes in expression of Bcl-
2 and Bcl-xL [28,29].
By autocrine/paracrine actions IGFs can increase the cell
turnover and the susceptibility of malignant cells. It was
already reported that IGFs inhibits the programmed cell
death [30]. Experiments using animal and cell culture
have shown that the antiapoptotic activity of IGF-I is
counterbalanced by the activity of IGFBP-3, which may
have a direct and independent-stimulating action on
apoptosis [31]. The predictive value of IGF-I may be useful
in screening for cancer. For example, the ratio of IGF-I to
prostate specific antigen may be a better predictor of the
development of prostate cancer than the antigen alone
[32].
Recent evidences suggest that silibinin, a commonly
occurring flavonoid can inhibit the IGF-I secretions, and
increase the level of IGFBP-3 and induce of apoptosis in
both in vivo and in vitro model of prostate cancer [33,34].
IGF-I interacts with IGF-IR to stimulate cell growth. Insu-
lin receptor substrate-I (IRS-I) is a key signaling molecule
activated by IGFs. Increased IRS-I tyrosine phosphoryla-
tion by IGFs is directly correlated with increased activa-
tion of the downstream effector molecules
phosphatidylinositol 3' kinase and mitogen activated pro-
tein kinase, and the growth response to IGFs is mediated
by these pathways [35,36]. It was reported that IGFBP-3
reduces the IRS-I tyrosine phorphorylation [34]. The
present results demonstrate that quercetin induces IGFBP-
3 secretions and that IGFBP-3 reduces the amount of
available ligands (IGFs) available for the interaction of
IGF-IR. Thus it appears that the antiproliferative action of
quercetin in androgen- independent PC-3 cells involves
increased IGFBP-3 production and induction of apopto-
sis. Furthermore, quercetin also deserves study in the con-
text of prostate cancer preventions, because others have
recently shown in populations studies that higher circulat-
ing IGFs level and/or lowers IGFBP-3 levels are associated
with increased risk of prostate cancer [37,38]. It is relevant
that the quercetin shown to be nontoxic in humans
includes the possibility that this compound may be useful
in prostate cancer treatment. There is also evidence that
IGFBP-3 can induce apoptosis by itself, as well as potenti-
ate the apoptotic effects of other factors such as ionizing
and UV irradiation and chemotherapeutic agents [39-41].
Hence, the present study demonstrates that quercetin is
capable of mediating growth inhibition against prostate
cancer cells in vitro and is pro-apoptotic. As quercetin is
able to induce apoptosis in PC-3 cells, the present findings
suggest that quercetin-induced apoptosis could be medi-
ated by the down regulation of IGFs and up regulation of
IGFBP-3 in PC-3 cells. Therefore, quercetin can be consid-
ered for the evaluation of their in vivo or clinical efficacy
against prostate cancer.
Conclusion
This data raise the possibility that IGFBP-3 is the positive
regulator of quercetin-induced apoptosis in PC-3 cells as
IGFBP-3 is reported to induce apoptosis in various cancer
cell lines. The increased level of IGFBP-3 was associated
with increased pro-apoptotic proteins and apoptosis in
response to quercetin, suggesting it may be mediated via
its modulation of the Bax: Bcl-2 protein ratio and hypoth-
esize that IGFBP-3 act as an effector of quercetin induced-
apoptosis in prostate cancer cells. The role of IGFBP-3 as
an effector of p53-independent apoptotic pathways has
particular relevance in the treatment of prostate cancer,
where inactivating mutations in the p53 gene occur at
high frequency. Hence our data raise the possibility that
IGFBP-3 is the positive regulator of quercetin-induced
apoptosis and quercetin may have some therapeutic value
for prostate cancer.
Note
Table 1 Effect of quercetin on IGF-I, -II and IGFBP-3 secre-
tion by the PC-3 cells. Cells were seeded at a density of 1
× 106/cm2 in 100 mm petri dishes and the medium then
replaced with quercetin containing medium. After 24 h
and 48 h, media were collected and quantified for IGF-I, -
II and IGFBP-3. The results shown are those for five sepa-Journal of Carcinogenesis 2006, 5:10 http://www.carcinogenesis.com/content/5/1/10
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rate experiments. *-denotes the statistical significance at P
< 0.05 level between control and quercetin treatment
groups using Student's Newman Keuls (SNK) test. ND –
Not detectable.
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